Clinical trials · Georgia
Crohn’s disease clinical trials in Georgia
We’re tracking 26 recruiting crohn’s disease studies with a site in Georgia — including Phase 1, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Georgia
- NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Atlanta, GeorgiaAges 18–85 - NCT07483099RecruitingPhase 2
Study of two drugs for Crohn's disease
This trial tests if taking a new drug (LY4395089) with mirikizumab works better than mirikizumab alone for adults with Crohn's disease. It also looks at the safety of these treatments.
Atlanta, GeorgiaAges 18–80 - NCT07499232RecruitingPhase 3
Guselkumab vs Risankizumab for Crohn's disease
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
Atlanta, GeorgiaAges 18 years+ - NCT07577843RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe Crohn's disease
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
Suwanee, GeorgiaAges 18 years+ - NCT07196722RecruitingPhase 2/Phase 3
Testing icotrokinra for moderate to severe Crohn's disease
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Atlanta, GeorgiaAges 18 years+ - NCT05781152RecruitingPhase 4
Testing how new Crohn’s imaging and scopes predict outcomes
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
Atlanta, GeorgiaAges 6–17 - NCT06045754RecruitingPhase 4
Study of vedolizumab with other drugs for Crohn's disease
This trial tests whether combining vedolizumab with adalimumab or ustekinumab helps people with moderate to severe Crohn's disease who haven't responded to other treatments. It aims to find better ways to manage symptoms and improve quality of life.
Roswell, GeorgiaAges 18–70 - NCT05509777RecruitingPhase 3
Mirikizumab for children with active Crohn’s disease
This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.
Atlanta, GeorgiaAges 2–17 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Atlanta, GeorgiaAges 2–17 - NCT06548542RecruitingPhase 2
Targeted therapy study for moderate to severe Crohn's disease
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
Macon, GeorgiaAges 18–75 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Atlanta, GeorgiaAges 18–75 - NCT06958536RecruitingPhase 2
Testing a new drug for moderate to severe Crohn's disease
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
Marietta, GeorgiaAges 18–75 - NCT07184931RecruitingPhase 3
Testing duvakitug for active Crohn's disease
This study tests a new drug called duvakitug for people with moderately to severely active Crohn's disease who haven't responded well to other treatments. It aims to see if the drug can reduce symptoms and improve quality of life.
Atlanta, GeorgiaAges 16–80 - NCT04779320RecruitingPhase 3
Vedolizumab for teens with moderate to severe Crohn's
This trial tests vedolizumab to treat children and teens with moderate to severe Crohn’s disease when standard treatments haven’t worked or caused side effects. It may help reduce gut inflammation and symptoms and help some patients stay healthier over time.
Atlanta, GeorgiaAges 2–17 - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Atlanta, GeorgiaAges 18–80 - NCT04844606RecruitingPhase 3
Mirikizumab for kids with ulcerative colitis or Crohn’s
This study checks whether continuing mirikizumab (a medicine that calms gut inflammation) helps children with ulcerative colitis or Crohn’s disease after prior study treatment. It aims to see if staying on the medicine is beneficial and safe over time.
Atlanta, GeorgiaAges 2–19 - NCT06430801RecruitingPhase 3
Study of tulisokibart for moderate to severe Crohn's disease
This trial tests a new medicine called tulisokibart for people with moderate to severe Crohn's disease. The medicine may help reduce inflammation and improve symptoms. It is for those who have not had success with other treatments.
Atlanta, GeorgiaAges 16–80 - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Atlanta, GeorgiaAges 2 years+ - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Atlanta, GeorgiaAges 16–80 - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Atlanta, GeorgiaAges 16–80 - NCT06424769Enrolling by invitation
Managing Inflammatory Bowel Disease with Text Message Surveys
This study aims to improve care and reduce health gaps for people with inflammatory bowel disease using text-message surveys to track symptoms and guide better disease management.
Atlanta, GeorgiaAges 13 years+ - NCT02791854Enrolling by invitation
Improving Care for Adults With Crohn’s or Ulcerative Colitis
This trial looks at ways to improve care for adults living with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. You may be invited if your clinic is part of an inflammatory bowel disease care network called IBD Qorus.
Atlanta, GeorgiaAges 18–99 - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
Atlanta, GeorgiaAges 18–80 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Atlanta, GeorgiaAges 18 years+
Crohn’s disease trials by city in Georgia
Where these studies are running in Georgia
Institutions with a site for the recruiting crohn’s disease studies listed above.
- Atlanta Gastroenterology Associates · 7 studies
- Emory University · 7 studies
- Children's Center for Digestive Health Care · 6 studies
- Gastroenterology Associates of Central Georgia · 5 studies
- Morehouse School of Medicine · 4 studies
- Atlanta Center for Gastroenterology, P.C. · 3 studies
- Digestive Healthcare of Georgia · 2 studies
- Atlanta Gastroenterology Specialists PC
What taking part in a crohn’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Crohn’s disease trials in other states
Common questions
- Are there crohn’s disease clinical trials in Georgia?
- Yes. We're currently tracking 26 recruiting crohn’s disease studies with a site in Georgia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a crohn’s disease study in Georgia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Georgia to take part?
- Not necessarily. These studies have a site in Georgia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a crohn’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New crohn’s disease studies open in Georgia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.